bioXXmed AG Logo

bioXXmed AG

ISIN: DE000A0KFRJ1 | Ticker: T5O | LEI: 8945005J8KVO36IW6P49

About bioXXmed AG

Company Description

bioXXmed AG, based in Darmstadt, Germany, is a holding company that invests equity in innovative biotechnology or medical technology companies. bioXXmed AG (formerly Cytotools AG) has been listed on the Basic Board of the Frankfurt Stock Exchange since 2006.

bioXXmed AG finances biomedical projects in independent investment companies via equity contributions, alone or in consortium with other investors. Depending on the investment case, the holding period of the investments varies, but the aim is a long-term investment. As an active portfolio manager and investor, bioXXmed AG works closely with the management of the companies to ensure the success and long-term viability of the investment.

Currently, bioXXmed AG has a 68 percent stake in DermaTools Biotech GmbH and is the largest shareholder in Cytopharma GmbH. Beyond the existing investments, bioXXmed AG intends to invest in further innovative projects.

Year founded

2000

Served area

Worldwide

Headquarters

Riedstrasse 2, 64295 Darmstadt – Germany

Filings & Publications

2021

Report Q1 H1 Q3 FY
Consolidated Report GER
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Shareholder information

Shares outstanding

5,140,000

IPO

Aug. 1, 2016

Stock exchange(s)

Frankfurt Stock Exchange

Contact Investor Relations department

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.